Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to <100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPANDPaola Guglielmelli, Heinz Gisslinger, Guangsheng He et al.|Therapeutic Advances in Hematology|2022Cited by 11
Ruxolitinib in Pediatric Patients with Treatment-<i>Naïve</i> or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 StudyFranco Locatelli, Cristina Díaz de Heredia, Hyoung Jin Kang et al.|Blood|2022Cited by 11
The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to &lt; 100 × 109/L) at BaselinePaola Guglielmelli, Heinz Gisslinger, Jean‐Jacques Kiladjian et al.|Blood|2020Cited by 7